Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:30:06 EST Wed 14 Jan 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:CMPS - COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS - https://compasspathways.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CMPS - Q0.17.35·7.730.27.37+0.375.31,270.18,7307,9517.07  7.3999  6.878.20  2.25Jan 13Jan 0715 min RT 2¢

Recent Trades - Last 10 of 7951
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-07 06:30U:CMPSNews ReleaseCompass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
2026-01-06 06:30U:CMPSNews ReleaseCompass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
2025-12-09 06:30U:CMPSNews ReleaseCompass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET
2025-11-20 06:30U:CMPSNews ReleaseCompass Pathways to Participate in Two Investor Conferences in December
2025-11-05 06:30U:CMPSNews ReleaseCompass Pathways to Participate in Stifel 2025 Healthcare Conference
2025-11-04 06:30U:CMPSNews ReleaseCompass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
2025-10-30 08:30U:CMPSNews ReleaseNeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
2025-10-29 06:30U:CMPSNews ReleaseCompass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
2025-10-28 06:30U:CMPSNews ReleaseCompass Pathways to Announce Third Quarter Financial Results on November 4, 2025
2025-09-10 16:01U:CMPSNews ReleaseDesign Therapeutics Appoints Justin Gover to Board of Directors
2025-09-02 06:30U:CMPSNews ReleaseCompass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
2025-08-27 06:30U:CMPSNews ReleaseCompass Pathways to Participate in Four Investor Conferences in September
2025-08-05 06:30U:CMPSNews ReleaseCompass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
2025-07-31 06:30U:CMPSNews ReleaseCompass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
2025-07-29 06:30U:CMPSNews ReleaseCompass Pathways Appoints Justin Gover to Board of Directors
2025-07-22 06:30U:CMPSNews ReleaseCompass Pathways to Announce Second Quarter Financial Results on July 31, 2025
2025-07-10 16:00U:CMPSNews ReleaseCompass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
2025-07-01 09:50U:CMPSNews ReleaseGlobal Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
2025-06-23 06:30U:CMPSNews ReleaseCompass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
2025-05-14 06:30U:CMPSNews ReleaseCompass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference